All In Biotech

Drug Trial Radar · NCT03052010

The Partners Scale-Up Project

Delivery of Integrated PrEP and ART for Couples in Kenya

Last checked: Nov 19, 2026Latest source record: Oct 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4,898

Actual

Start

Feb 6, 2017

Primary completion

Dec 15, 2020

Study completion Apr 30, 2021

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kenya Medical Research Institute; Kenya National AIDS & STI Control Programme; National Institute of Mental Health (NIMH); Bill and Melinda Gates Foundation
First posted
Feb 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An implementation project to scale-up delivery of antiretroviral-based HIV-1 prevention methods to Kenyan HIV-1 serodiscordant couples in HIV-1 care centers. Pre-exposure prophylaxis (PrEP) as a bridge to antiretroviral therapy (ART) HIV-1 prevention strategy will be introduced into 24 public HIV-1 care centers in central and western Kenya according to national guidelines using a stepped wedge design, stratified by region.

Conditions

  • HIV-1-infection

Interventions

  • Integrated PrEP as a bridge to ART HIV-1 prevention strategyOther

    The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services

  • PrEPDrug

    A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.

  • ARTDrug

    ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of HIV-1 infected persons whose partners are tested for HIV-1 before/after PrEP as a bridge to ART is implementedTime frame: up to 36 months
  2. PrEP initiationTime frame: up to 36 months
  3. PrEP adherenceTime frame: up to 6 months
  4. HIV-1 uninfected partners staying HIV-1 uninfected.Time frame: up to 36 months
  5. ART initiationTime frame: up to 36 months
  6. ART adherenceTime frame: up to 6 months
  7. Facilitators and barriers to implementation of integrated PrEP and ARTTime frame: up to 36 months
  8. PrEP delivery operational toolsTime frame: 24 months
  9. Cost and cost-effectiveness of the integrated PrEP and ART when delivered in public health clinics.Time frame: up to 36 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • KEMRI

    Kisumu, Kenya

  • Partners in Health Research and Development

    Thika, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.